Heron Therapeutics (HRTX) Receivables (2010 - 2026)

Heron Therapeutics has reported Receivables for 12 years, with the latest figure at $83.7 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 6.3% year-over-year to $83.7 million; the trailing twelve-month figure through Mar 2026 stood at $83.7 million (up 6.3% YoY), and the FY2025 full-year result was $89.9 million, up 13.63% from the prior year.
• Receivables for Q1 2026 stood at $83.7 million, down from $89.9 million in the prior quarter.
• The five-year high for Receivables was $89.9 million in Q4 2025, with the low at $40.3 million in Q2 2022.
• Historically, Receivables has averaged $66.6 million across 5 years, with a median of $67.0 million in 2024.
• Annual changes were most pronounced in 2022 — Receivables decreased 5.43% — and 2023, when it jumped 90.29%.
• Heron Therapeutics' Receivables stood at $58.2 million in 2022, then increased by 3.78% to $60.4 million in 2023, then soared by 30.93% to $79.1 million in 2024, then gained by 13.63% to $89.9 million in 2025, then fell by 6.94% to $83.7 million in 2026.
• The last three Receivables figures came in at $83.7 million (Q1 2026), $89.9 million (Q4 2025), and $81.0 million (Q3 2025), per Business Quant data.